![John Shiver](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
John Shiver
Directeur/Membre du Conseil chez
NOVAVAX, INC.
Fortune : 74 463 $ au 31/08/2026
Profil
John W.
Shiver is Director at International AIDS Vaccine Initiative, Inc. since 2018.
Dr. Shiver is Independent Director at Novavax, Inc. starting 2025.
Dr. Shiver is Director at Calder Biosciences, Inc. Dr. Shiver is Director at AuraVax Therapeutics, Inc. Dr. Shiver is Special Advisor at F-Prime Inc. since 2022.
Formerly, Dr. Shiver was President & Director at Sanofi Pasteur VaxDesign Corp.
Dr. Shiver was Independent Director at Icosavax, Inc. from 2022 to 2024.
Dr. Shiver was Vice President-Vaccine & Biologics Basic Research at Merck & Co., Inc. Dr. Shiver was Chief Strategy Officer-Infectious Diseases Unit at IGM Biosciences, Inc. from 2021 to 2023.
Dr. Shiver earned a doctorate from the University of Florida in 1985.
Dr. Shiver earned an undergraduate degree from Wofford College in 1978.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 18/06/2026 | 7 947 ( 0% ) | 74 463 $ | 31/08/2026 |
Postes actifs de John Shiver
| Sociétés | Poste | Début |
|---|---|---|
| NOVAVAX, INC. | Directeur/Membre du Conseil | 10/03/2025 |
International AIDS Vaccine Initiative, Inc.
 International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops vaccines for AIDS | Directeur/Membre du Conseil | 01/09/2018 |
Impresa Management LLC
 Impresa Management LLC Investment ManagersFinance F-Prime invests in companies located in Asia, Europe, North America and South America. The firm targets companies operating in the fields of life sciences, technology, healthtech & services and crypto sectors. It provides financing for seed, early and later stage transactions. | Consultant / Advisor | 01/11/2022 |
AURAVAX THERAPEUTICS, INC. | Directeur/Membre du Conseil | - |
Calder Biosciences, Inc.
 Calder Biosciences, Inc. BiotechnologyHealth Technology Develops vaccine immunogens | Directeur/Membre du Conseil | - |
Anciens postes connus de John Shiver
| Sociétés | Poste | Fin |
|---|---|---|
| ICOSAVAX, INC. | Directeur/Membre du Conseil | 19/02/2024 |
| IGM BIOSCIENCES, INC. | Corporate Officer/Principal | 01/12/2023 |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
Sanofi Pasteur VaxDesign Corp.
 Sanofi Pasteur VaxDesign Corp. Miscellaneous Commercial ServicesCommercial Services Develops, manufactures, & markets in vitro models of human immune systems | President | - |
Formation de John Shiver
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
72
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Novavax, Inc.
 Novavax, Inc. BiotechnologyHealth Technology Engages in development of novel recombinant vaccines | Health Technology |
International AIDS Vaccine Initiative, Inc.
International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops vaccines for AIDS | Health Technology |
University of Florida
 University of Florida Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Wofford College
 Wofford College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sanofi Pasteur VaxDesign Corp.
Sanofi Pasteur VaxDesign Corp. Miscellaneous Commercial ServicesCommercial Services Develops, manufactures, & markets in vitro models of human immune systems | Commercial Services |
Impresa Management LLC
Impresa Management LLC Investment ManagersFinance F-Prime invests in companies located in Asia, Europe, North America and South America. The firm targets companies operating in the fields of life sciences, technology, healthtech & services and crypto sectors. It provides financing for seed, early and later stage transactions. | Finance |
IGM Biosciences, Inc.
 IGM Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops engineered IgM antibodies for the treatment of cancer patients | Health Technology |
Icosavax, Inc.
 Icosavax, Inc. BiotechnologyHealth Technology Develops vaccines for infectious disease | Health Technology |
Calder Biosciences, Inc.
Calder Biosciences, Inc. BiotechnologyHealth Technology Develops vaccine immunogens | Health Technology |
AURAVAX THERAPEUTICS, INC. |
